The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study

✍ Scribed by Watkins, D.J.; Starling, N.; Cunningham, D.; Thomas, J.; Webb, J.; Brown, G.; Barbachano, Y.; Oates, J.; Chau, I.

• Book ID: 122158773
• Publisher: Elsevier Science
• Year: 2014
• Tongue: English
• Weight: 446 KB
• Volume: 50
• Category: Article
• ISSN: 0959-8049
• DOI: 10.1016/j.ejca.2014.02.003